# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 41-50 of 573 results.
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 30, 2019
First Received: Jun 28, 2019
Disease(s): Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Intervention(s): TQB2450
Locations: Peking University First Hospital, Beijing, Beijing, China
Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijin, Beijing, China
Peking Hospital, Beijin, Beijing, China
... and 14 other locations.
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 14, 2015
First Received: May 20, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Locations: DiDeng, Wuhan, Hubei, China
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Dec 10, 2019
First Received: Sep 07, 2017
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Southern Cancer Center, Daphne, Alabama, United States
City of Hope, Duarte, California, United States
Ronald Reagan UCLA Medical Center; Drug Information Center, Los Angeles, California, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
... and 253 other locations.
The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 14, 2015
First Received: May 20, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Locations: DiDeng, Wuhan, Hubei, China
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation
Status: Recruiting
Last Changed: Apr 24, 2019
First Received: Feb 26, 2016
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Ibrutinib, Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone
Locations: Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
Hospital Especialidades, Jerez de la Frontera, Cádiz, Spain
Hospital Universitario Donostia, Donostia San Sebastian, Guipúzcoa, Spain
Hospital Universitario Son Espases, Palma, Islas Baleares, Spain
Hospital de Navarra, Pamplona, Navarra, Spain
... and 13 other locations.
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Sep 14, 2018
First Received: Jul 06, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Decitabine
Locations: Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: May 03, 2019
First Received: May 03, 2019
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): abexinostat
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Status: Recruiting
Last Changed: Jan 04, 2019
First Received: Jun 15, 2015
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): KPT-330, Rituximab, Etoposide, Carboplatin, Ifosfamide, Dexamethasone
Locations: Weill Cornell Medical College, New York, New York, United States
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Oct 11, 2019
First Received: Jun 20, 2019
Disease(s): Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention(s): ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 21, 2019
First Received: Nov 07, 2016
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Locations: Münster University Hospital, Münster, Germany